Design and rationale of the EBBINGHAUS trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the FOURIER trial

Lignende værker

• Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
  af: Gencer, Baris, et al.
  Udgivet: (2020)
• Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
  af: Qamar, Arman, et al.
  Udgivet: (2018)
• Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
  af: Wiviott, Stephen D., et al.
  Udgivet: (2020)
• No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.
  af: Laura E Korthauer, et al.
  Udgivet: (2022-01-01)
• No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
  af: Laura E. Korthauer, et al.
  Udgivet: (2022-01-01)